Dr. Reddy's Laboratories Limited has announced amendments to its Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information, following approval by the Board of Directors on March 24, 2026. The updated code ensures strict compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, establishing comprehensive frameworks for managing sensitive financial information.

Key Code Provisions

The amended code introduces several critical compliance measures for handling unpublished price sensitive information (UPSI). The company has designated its Head of Investor Relations as the Chief Investor Relations Officer, responsible for ensuring uniform and universal disclosure practices across all stakeholder communications.

Information Handling Protocols

The code establishes strict "need to know" protocols for UPSI distribution within the organization. Information sharing is restricted to individuals requiring access for legitimate business purposes, duty performance, or legal obligation discharge. The company has explicitly prohibited disclosure of UPSI through social media platforms, with mandatory public dissemination required within 24 hours of any inadvertent disclosure.

Legitimate Purpose Framework

UPSI sharing with external parties is permitted exclusively for legitimate purposes, including interactions with:

• Partners and collaborators
• Lenders, customers, and suppliers
• Merchant bankers and legal advisors
• Auditors and insolvency professionals
• Other authorized consultants

All recipients of UPSI for legitimate purposes are considered insiders and must receive formal notice outlining confidentiality duties, responsibilities, and liabilities. The company requires Permanent Account Number (PAN) or alternative legal identifiers from all information recipients.

Database Management Requirements

The Chief Executive Officer, under Board supervision, maintains a comprehensive digital database documenting UPSI nature, sharing personnel, and recipient details including PAN information. This structured database requires preservation for minimum eight years from transaction completion, with extended retention during SEBI investigations or enforcement proceedings.

Regulatory Compliance Framework

The code emphasizes fair stakeholder treatment during analyst and investor interactions, ensuring no selective advantages through preferential information access. Official documentation through transcripts and recordings of investor conferences will be made available on the company website as required by applicable regulations.

Implementation and Review

The Board retains authority for periodic code review and amendments, ensuring alignment with evolving SEBI regulations and listing requirements. In cases of inconsistency between the code and applicable SEBI laws, regulatory provisions will override company policies. The comprehensive framework demonstrates the company's commitment to transparent information disclosure practices and regulatory compliance in capital market operations.

Dr. Reddy's Laboratories Ltd. has officially announced a board meeting scheduled for May 12, 2026, to consider the audited standalone and consolidated financial results for the fourth quarter and full financial year ending March 31, 2026. The pharmaceutical company communicated this development through formal notifications to stock exchanges on March 23, 2026.

Board Meeting Announcement

The meeting of the Board of Directors will specifically focus on reviewing and approving the audited financial results for Q4FY26 and FY26. This announcement has been made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for material information disclosure.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, Dr. Reddy's Laboratories has announced the closure of its trading window for company securities. The restriction will be effective from March 25, 2026, to May 14, 2026, both days inclusive.

Exchange Notifications

The company has formally notified multiple stock exchanges where its securities are listed, including the National Stock Exchange of India Ltd. (Scrip Code: DRREDDY), BSE Limited (Scrip Code: 500124), New York Stock Exchange Inc. (Stock Code: RDY), and NSE IFSC Ltd. (Stock Code: DRREDDY). The notification was digitally signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.

Corporate Governance Compliance

This announcement reflects Dr. Reddy's Laboratories' commitment to maintaining transparent corporate governance practices and regulatory compliance. The trading window closure is a standard requirement designed to prevent insider trading during periods when material financial information is being finalized and before its public disclosure across all trading platforms where the company's securities are available.